Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 3/20 | 0.49 |
| ▸ | GRM5 | P41594 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28754501 | 0.79 | GRM1 (0.42) | GRM1GRM5CYP2D6EGFRLMNA | |
| SCHEMBL42370 | 0.78 | EGFR (0.51) | EGFRKMT2ATSHRHSD17B10AKR1B1 | |
| SCHEMBL7709177 | 0.77 | GRM1 (0.44) | GRM1GRM5CYP2D6EGFRLMNA | |
| Ammonia Solution, Strong SCHEMBL27729485 | 0.76 | EGFR (0.50) | EGFRKMT2ATSHRHSD17B10AKR1B1 | |
| SCHEMBL7589860 | 0.74 | HTR2A (0.53) | CYP2D6EGFRLMNAMEN1KMT2A | |
| SCHEMBL11114720 | 0.74 | EGFR (0.49) | EGFRLMNATSHRAKR1B1CDC25A | |
| SCHEMBL11055807 | 0.74 | GRM5 (0.53) | GRM1GRM5CYP2D6LMNAMEN1 | |
| SCHEMBL6435659 | 0.74 | GLA (0.40) | GRM1GRM5EGFRMEN1KMT2A | |
| SCHEMBL5756547 | 0.74 | GRM1 (0.51) | GRM1GRM5CYP2D6LMNAMEN1 | |
| SCHEMBL1389876 | 0.73 | HTR2A (0.55) | CYP2D6EGFRTSHRCHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602955-B | Photocuring method, compound used in photocuring method, and composition | 富士胶片和光纯药株式会社 | 2021-08-06 | — | — | CN | disclosed |
| US-8034940-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034940-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-11 | — | — | US | disclosed |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | disclosed |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | disclosed |
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | disclosed |
| WO-2008021926-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| CN-1886391-A | Teramic acid and threonine as beta-secretase inhibitors | HOFFMANN LA ROCHE (CH) | 2006-12-27 | — | — | CN | disclosed |
| EP-1689729-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. Hoffmann-La Roche AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005058857-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | disclosed |
| US-3981887-A | Sulfoxides and sulfones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | BACE1, PSEN1, BACE2 | GRM1 422/4885GRM5 289/4885CYP2D6 2202/4885 |
| US-20050119329-A1 | Tetronic and tetramic acids | BACE1, PSEN1, BACE2 | GRM1 422/4885GRM5 289/4885CYP2D6 2202/4885 |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFKB2, NFRKB, NFKB1 | GRM1 336/4885GRM5 1198/4885CYP2D6 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.